David Adams is a Senior Group Leader at the Wellcome Trust Sanger Institute. By developing and applying new genomic technologies and experimental model systems, Dr Adams has redefined our understanding of key processes that control tumour growth, metastasis and predisposition to tumour formation. He has also generated the largest ever collection of genetically modified mouse lines which have been distributed to researchers around the globe facilitating key insights in areas such as brain and bone development, infection and immunology, and metabolism. Dr Adams also leads the mouse genomes project which has sequenced and analysed over 40 mouse strains and released these data to the research community.
Fellow
Back to directory listingDr David Adams FMedSci
Job Title
Senior Group Leader
Department
Cancer Ageing and Somatic Mutation
Institution
Wellcome Trust Sanger Institute
Year elected
2018
Interests
SpecialitiesCancer genetics, functional genomics, gene editing
Section committee elected byCellular and developmental biology, microbiology and immunology, genetics
Online Information